Loading...
In 2016, two trials were published in which researchers examined established uses of supplemental oxygen. These results raise questions about our current practices.
A multicenter U.S. trial included 738 patients with chronic obstructive pulmonary disease (COPD) and mild-to-moderate resting hypoxemia (oxyhemoglobin saturation [SpO2], 89%–93%) or moderate exertional hypoxemia (SpO2, <90% for ≥10 seconds, but ≥80% for ≥5 minutes during a 6-minute walk test). Patients were randomized to supplemental oxygen or no supplemental oxygen. During 18 months of follow-up, investigators found no differences between groups in mortality, hospitalization rates, quality of life, or lung function (NEJM JW Gen Med Dec 1 2016 and N Engl J Med 2016; 375:1617).
In …